ATE303793T1 - Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes - Google Patents

Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes

Info

Publication number
ATE303793T1
ATE303793T1 AT02713167T AT02713167T ATE303793T1 AT E303793 T1 ATE303793 T1 AT E303793T1 AT 02713167 T AT02713167 T AT 02713167T AT 02713167 T AT02713167 T AT 02713167T AT E303793 T1 ATE303793 T1 AT E303793T1
Authority
AT
Austria
Prior art keywords
active ingredient
pharmaceutical composition
therapeutically active
core
prolonged
Prior art date
Application number
AT02713167T
Other languages
English (en)
Inventor
Sanjay Garg
Rajan Kumar Verma
Chaman Lal Kaul
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Application granted granted Critical
Publication of ATE303793T1 publication Critical patent/ATE303793T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02713167T 2001-01-30 2002-03-22 Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes ATE303793T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN96DE2001 2001-01-30
PCT/IN2002/000062 WO2003063825A1 (en) 2001-01-30 2002-03-22 Pharmaceutical composition for extended/sustained release of therapeutically active ingredient

Publications (1)

Publication Number Publication Date
ATE303793T1 true ATE303793T1 (de) 2005-09-15

Family

ID=27638221

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713167T ATE303793T1 (de) 2001-01-30 2002-03-22 Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes

Country Status (10)

Country Link
US (1) US20030175349A1 (de)
EP (1) EP1469824B1 (de)
JP (1) JP2006508891A (de)
KR (1) KR100878882B1 (de)
CN (1) CN1301706C (de)
AT (1) ATE303793T1 (de)
DE (1) DE60206078T2 (de)
ES (1) ES2248529T3 (de)
WO (1) WO2003063825A1 (de)
ZA (1) ZA200406112B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
MXPA04003807A (es) 2001-11-30 2004-07-30 Pfizer Prod Inc Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
AU2003300692A1 (en) * 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
EP1916994B1 (de) * 2004-06-29 2013-12-11 Takeda Pharma A/S Herstellung einer pharmazeutischen zusammensetzung mit schneller freisetzung aus wasserunlöslichen arzneimitteln und mit dem erfindungsgemässen verfahren erhaltene pharmazeutische zusammensetzungen
MX2007001138A (es) * 2004-07-29 2007-04-19 Sanofi Aventis Comprimido farmaceutico multicapa para la liberacion controlada de ingredientes activos con solubilidad muy dependiente del ph.
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
WO2007027566A2 (en) 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
CA2622693C (en) 2005-09-15 2015-05-05 Genzyme Corporation Sachet formulation for amine polymers
US7709014B2 (en) * 2005-10-17 2010-05-04 Yu Ruey J Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites
KR100702069B1 (ko) * 2005-10-31 2007-03-30 (주)이엘티사이언스 파라세타몰 경구용 수용산제 복합조성물 및 그 제조방법
US20110178112A1 (en) * 2006-01-18 2011-07-21 Evolva Sa PPAR Modulators
CN101420939A (zh) * 2006-04-24 2009-04-29 辉瑞产品公司 用于药物递送装置的不对称膜
US20070269492A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
EP2066293A2 (de) 2006-09-29 2009-06-10 Genzyme Corporation Amid-dendrimer-zusammensetzungen
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
JP5812318B2 (ja) 2007-12-04 2015-11-11 レメディー ファーマシューティカルズ， インコーポレイテッド 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
CN101259113B (zh) * 2008-04-21 2013-02-13 沈阳药科大学 依托度酸渗透泵型控释制剂
EP2228066A1 (de) * 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmazeutische Zusammensetzungen eines auf Sulphonylharnstoff basierenden pharmazeutischen Wirkstoffs mit ausgezeichneten Auflösungseigenschaften
CN101618027B (zh) * 2009-07-16 2013-07-31 沈阳药科大学 醋氯芬酸双层渗透泵控释片及其制备方法
US9005661B2 (en) * 2009-09-15 2015-04-14 Beijing Team Hospital Management Co., Ltd. Osmotic pump controlled release tablet and preparation method thereof
CN102670575A (zh) * 2011-03-09 2012-09-19 中国药科大学 酮洛芬渗透泵型控释制剂及其制备方法
CN102133205B (zh) * 2011-03-17 2013-12-11 山东新华制药股份有限公司 一种格列吡嗪渗透泵控释片的制备方法
EP2760821B1 (de) * 2011-09-02 2017-10-11 Novartis AG Cholinsalz aus einer entzündungshemmenden substituierten cyclobutendion-verbindung
CN103142565B (zh) * 2012-04-18 2015-04-29 中国人民解放军军事医学科学院毒物药物研究所 一种尼美舒利的缓释药物组合物及其制备方法
ES2655622T3 (es) * 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
US9861585B2 (en) 2012-10-16 2018-01-09 Sun Pharmaceutical Industries Limited Osmotic floating tablets
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
DE102015122319A1 (de) * 2015-12-18 2017-06-22 Special Coatings Gmbh & Co. Kg Trommelbeschichtungsverfahren und -vorrichtung für kleine mengen an zu beschichtenden kleinteilen
GB2546513B (en) 2016-01-20 2020-09-16 Cubic Pharmaceuticals Ltd Process of preparing active pharmaceutical ingredient salts
CN105581993B (zh) * 2016-03-11 2018-06-29 常州欧法玛制药技术有限公司 一种阿司匹林渗透泵控释片及其制备方法
CN109303765A (zh) * 2018-11-21 2019-02-05 南京泽恒医药技术开发有限公司 一种呋塞米口服溶液及其制备方法
KR20220101150A (ko) * 2019-11-14 2022-07-19 화이자 인코포레이티드 1-(((2s,3s,4s)-3-에틸-4-플루오로-5-옥소피롤리딘-2-일)메톡시)-7-메톡시이소퀴놀린-6-카복사마이드 조합물 및 경구 투여 형태
UY39658A (es) * 2021-03-04 2022-09-30 Biogen Chesapeake Llc Formulación y métodos de gliburida de baja absorción

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
DE2831164A1 (de) * 1978-07-15 1980-01-24 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
NZ226179A (en) * 1987-09-24 1991-04-26 Merck & Co Inc Controlled porosity osmotic pump for sustained release of pharmaceutical agents
JPH0791184B2 (ja) * 1988-03-31 1995-10-04 田辺製薬株式会社 放出制御型製剤およびその製法
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
TW235239B (de) * 1992-11-20 1994-12-01 Pfizer
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
JP2003513033A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド 浸透圧制御放出薬剤送達装置
SE0001151D0 (sv) * 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition

Also Published As

Publication number Publication date
ZA200406112B (en) 2006-06-28
EP1469824A1 (de) 2004-10-27
JP2006508891A (ja) 2006-03-16
US20030175349A1 (en) 2003-09-18
CN1301706C (zh) 2007-02-28
KR100878882B1 (ko) 2009-01-15
KR20040091006A (ko) 2004-10-27
DE60206078T2 (de) 2006-07-13
EP1469824B1 (de) 2005-09-07
CN1622799A (zh) 2005-06-01
DE60206078D1 (de) 2005-10-13
ES2248529T3 (es) 2006-03-16
WO2003063825A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
DE60206078D1 (de) Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes
HRP20090209T1 (hr) Proizvodnja uređaja za dugotrajno oslobađanje lijeka sa polimerima na bazi poliuretana
HRP20100682T1 (hr) Formulacija tablete produljenog oslobadanja koja sadrzi pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
DE60036534D1 (de) Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung
DE69917866D1 (de) Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
IS6863A (is) Ný himnuhúð
PL1998762T3 (pl) Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
ATE286387T1 (de) Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
BRPI0611400B8 (pt) formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
ATE406870T1 (de) Filmförmige, zerfallsfähige zubereitungen zur wirkstoff-freisetzung und verfahren zu deren herstellung
EA200702520A1 (ru) Составы для изменения биофизических свойств слизистой оболочки
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
ATE464888T1 (de) Vorrichtung für die transdermale abgabe von wirkstoffen
DZ3473A1 (fr) Formulation pharmaceutique a liberation prolongee independante de la force ionique.
WO2009072334A1 (ja) 製剤用核粒子
BRPI0416298A (pt) método para manufatura de poliacroleìna
EA200300110A1 (ru) Композиция элетриптана в виде частиц
JP2005526061A5 (de)
MX2009003815A (es) Formulaciones farmaceuticas.
NO20025461L (no) Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
JP2002537246A5 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1469824

Country of ref document: EP